Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Andrew DeRyke

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Open Forum Infectious Diseases|June 29, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression AnalysisIgnacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, et al.
Jac-Antimicrobial Resistance|March 7, 2023
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearanceJason A Roberts, David P Nicolau, Ignacio Martin-Loeches, et al.
Journal of Medical Microbiology|April 22, 2022
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019James A Karlowsky, Sibylle H Lob, Aaron Khan, et al.
Journal of Global Antimicrobial Resistance|April 22, 2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Tsz K Khan, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Open Forum Infectious Diseases|June 29, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression AnalysisIgnacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, et al.
Jac-Antimicrobial Resistance|March 7, 2023
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearanceJason A Roberts, David P Nicolau, Ignacio Martin-Loeches, et al.
Journal of Medical Microbiology|April 22, 2022
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019James A Karlowsky, Sibylle H Lob, Aaron Khan, et al.
Journal of Global Antimicrobial Resistance|April 22, 2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Tsz K Khan, et al.
Pageof 5